Therapeutic Developement

MVT Biotechnology Therapeutic primary target:

  • a therapeutic for the management and treatment of HEV infection

MVT Biotechnology will pursue a strategy of developing a biological therapeutic candidate for the treatment of HEV.

HEV treatment

Treatment of HEV is generally palliative and supportive; there is no specific antiviral therapy licensed for treatment of HEV infection. In the cases of life-threatening infection, for instance in transplant patients or other immunocompromised patients (for instance leukaemia patients with perturbed immunological function) treatment has been attempted with ribavirin, a drug that whilst nucleoside-like in structure, works by lowering the intracellular GTP pools, thereby reducing the rate of viral replication. Treatment of HEV infection with ribavirin is off-label, is generally experimental and represents a last-ditch attempt by the physician to provide some antiviral therapy in response to a life-threatening infection.

The further development and differentiation of ribavirin (and its derivatives) has stopped due to the forthcoming patent expiry of ribavirin, therefore the likelihood of a major pharma company investing in specific indication-led development of ribavirin remains remote. The market is clearly open for a specific antiviral treatment for infection of high-risk groups with HEV.

Given the worldwide rising infection rate with hepatitis E, the increasing awareness of the public health challenges, the paucity of treatments, therapies and prophylactics for HEV, MVT Biotechnology is well placed to exploit major business opportunity in delivering much needed and lucrative therapies and vaccines.

Therapeutic Future Developement

Major pharma companies – over the last decades – strongly focused their R&D efforts on potential large blockbuster products in areas such as influenza, meningitis, malaria and HIV. Due to the attrition rates and development risks, their “blockbuster” focused R&D led to a lack of innovation and diminishing pipelines. At the same time, their large size and complicated processes limited their agility to enter niche markets and the attractive market segment of so called neglected diseases – disease areas with strong medical and economical need, especially in emerging and niche markets. This market segment has been penetrated by smaller biotech companies, which filled their pipelines with smaller - but due to the more favourable cost and risk profile - still attractive product profiles.

Therefore, the need of larger pharma companies to fill their empty pipelines and to launch a product to prove their market success, has led to an increasing number of license deals or complete company acquisitions between biotech and major pharma companies.

MVT Bio intends to develop a further pipeline, extending beyond the primary product, concentrating on profitable niche products.

Hepatitis E (HEV)

Unmet Medical Need

20 millions infections annually

3,4 millions symptomatic cases / annum
(chronic & acute)

70.000 deaths

3.000 stillbirths / annum

up to 25% mortality rate in pregnant women, and poor fetal outcomes

 

HEV Virus